+ Filter
Loading...
Custom Services order now ship next day

CD33

Anti-CD33 Recombinant Antibody Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs delivers cutting-edge recombinant antibodies specifically designed to target CD33, offering powerful tools for advancing biomedical research. Our dedication to supporting research and discovery is reflected in our diverse portfolio of high-quality recombinant products, crafted to meet the stringent requirements of scientists. We focus on delivering exceptional value, combining superior performance with cost-effectiveness. In addition to our premium antibody offerings, we provide expert technical support to help researchers enhance their experimental outcomes. Partnering with Creative Biolabs means accessing innovative solutions that drive scientific progress and foster impactful advancements in the biomedical field.

CD33: A Key receptor in Hematological Malignancies

CD33 is a cell surface receptor found on various cells, especially in certain diseases, where it plays a crucial role in the development and progression of hematological malignancies, including acute myeloid leukemia (AML). Its presence in leukemia cells makes CD33 an ideal target for therapeutic approaches. In clinical research, targeting CD33 has shown significant promise, offering potential treatments for AML. Monoclonal antibodies and antibody-drug conjugates targeting CD33 are being developed and tested in clinical trials, with the goal of selectively targeting and eliminating leukemia cells, offering a more focused and potentially less toxic alternative to traditional chemotherapy. Moreover, further understanding of CD33's involvement in disease mechanisms, as well as its interactions within the tumor microenvironment, could pave the way for combination therapies that improve treatment outcomes and enhance the effectiveness of existing therapies.

Alternative Names

CD33 molecule, CD33rSiglec, SIGLEC-3, SIGLEC3, p67

Background

Sialic-acid-binding immunoglobulin-like lectin (Siglec) plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or sialylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through the dephosphorylation of signaling molecules. One of the repressive effects of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K.

Anti-CD33 rAb Products

We provide premium anti-CD33 recombinant antibodies to support and accelerate research focused on the CD33 target in biological studies.

Cat. No. Product Name Target Species Host Species Applications
MOB-1148z Mouse Anti-CD33 Recombinant Antibody (clone 19C9) Human Mouse ELISA; FC; IF; IHC; IP; FuncS
TAB-119LC Mouse Anti-CD33 Recombinant Antibody Human Mouse ELISA; IF; RIA
HPAB-0083-LSX Human Anti-CD33 Recombinant Antibody Human; Cynomolgus monkey Human ELISA; FC
HPAB-1948LY Human Anti-CD33 Recombinant Antibody Human; Mouse Human FC; SPR; Block
TAB-H37 Anti-Human CD33 Recombinant Antibody (Gemtuzumab Ozogamicin) Human Human ELISA; FC; IP; FuncS; IF; Neut; IHC

Creative Quality Control

To meet customer needs, we have implemented a robust quality management system that guarantees the excellence of our products while offering exceptional technical support to our clients.

Fig.1 SDS-PAGE analysis of HPAB-0083-LSX. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-CD33 antibody
(Cat# HPAB-0083-LSX, Creative Biolabs).

Fig.2 SEC-HPLC analysis of HPAB-0083-LSX. (Creative Biolabs Original)Fig.2 SEC-HPLC analysis of anti-CD33 antibody
(Cat# HPAB-0083-LSX, Creative Biolabs).

Fig.3 DB analysis of HPAB-0083-LSX. (Creative Biolabs Original)Fig.3 DB analysis of anti-CD33 antibody
(Cat# HPAB-0083-LSX, Creative Biolabs).

Fig.4 ELISA analysis of HPAB-0083-LSX. (Creative Biolabs Original)Fig.4 ELISA analysis of anti-CD33 antibody
(Cat# HPAB-0083-LSX, Creative Biolabs).

Fig.5 WB analysis of TAB-119LC. (Creative Biolabs Original)Fig.5 WB analysis of anti-CD33 antibody
(Cat# TAB-119LC, Creative Biolabs).

Customer Reviews

Excellent
H**ins
Human Anti-CD33 Recombinant Antibody (Cat#: HPAB-0083-LSX)
The human anti-CD33 recombinant antibody was employed to assess the expression of CD33 on cell surfaces. In flow cytometry experiments, the antibody effectively detected and quantified CD33-positive cells, delivering critical data for cell population analysis.
9/Sep/2021
Excellent
Ch**e
Mouse Anti-CD33 Recombinant Antibody (clone 19C9) (Cat#: MOB-1148z)
In my research on immune cell interactions, I utilized the mouse anti-CD33 recombinant antibody, employing immunofluorescence staining for detection. The results were outstanding, with the antibody accurately identifying CD33 markers on cells, providing clear and precise visualization. This significantly advanced my study, offering deep insights into CD33's role in the immune response.
13/Jun/2022
Excellent
Cl**k
Anti-Human CD33 Recombinant Antibody (Gemtuzumab Ozogamicin) (Cat#: TAB-H37)
In my leukemia research, I utilized the anti-human CD33 recombinant antibody and employed flow cytometry for detection. The results were exceptionally reliable, with the antibody effectively identifying CD33 markers in leukemia cells. It provided accurate and consistent data, proving to be a valuable tool that greatly advanced my research and deepened my understanding of CD33's role in leukemia.
14/May/2023

rAb Production

With years of expertise in recombinant antibody production and optimization, our company delivers high-quality products in a timely manner. We are committed to providing top-tier recombinant antibodies, adhering to the highest production standards and offering exceptional customer service throughout the process.

Featured Anti-CD33 Recombinant Antibody Production PlatformsFig.6 Anti-CD33 recombinant antibody production: milligram-scale. (Creative Biolabs Original)
Fig.6 Milligram-scale recombinant antibody production.

Fig.7 Anti-CD33 recombinant antibody production: gram-scale. (Creative Biolabs Original)Fig.7 Gram-scale recombinant antibody production.

rAb Modalities

Creative Biolabs is committed to providing researchers with a broad selection of high-quality recombinant antibodies in diverse formats. These include, but are not limited to, full-length, Fab, scFv, scFab, and full-length antibodies with various Fc isotypes. Our expertise spans a wide array of recombinant antibody engineering techniques, and we offer exceptional custom engineering services tailored to meet your specific requirements.

Fig.8 Diverse anti-CD33 recombinant antibody production and modalities. (Creative Biolabs Original)Fig.8 Diverse anti-CD33 recombinant antibody production and modalities.

Drug Information Targeting CD33

Table 1. Therapeutic approaches targeting CD33 in clinical development.

Research phase Company Classification Indications Details
Launched - 2000 Celltech Drug Conjugates Acute myeloid leukemia It is an anti-CD33 humanized antibody linked with calicheamicin, a potent antitumor antibiotic isolated by Wyeth Pharmaceuticals (now Pfizer) from a bacterium in caliche clay, a soil found in Texas.
Phase II Actinium Pharmaceuticals Drug Conjugates Acute myeloid leukemia It is an actinium-radiolabeled humanized monoclonal antibody targeting CD33, is in phase II clinical development at Actinium Pharmaceuticals for the treatment of patients 60 years and older with newly diagnosed acute myeloid leukemia (AML).
Phase I/II Actinium Pharmaceuticals Drug Conjugates Acute myeloid leukemia It is a humanized monoclonal antibody targeting CD33 (HuM195) that has completed early clinical trials by Actinium Pharmaceuticals and Memorial Sloan-Kettering Cancer Center for the treatment of acute myeloid leukemia.
Phase I Amgen Biologics Acute myeloid leukemia This is being evaluated in an early phase I clinical trial at Amgen for the intravenous treatment of adult patients with relapsed or refractory acute myeloid leukemia. In 2020, the company paused product development while gathering further information on the CD33 program through a progression of AMG-330.
Phase I Amphivena Therapeutics Biologics Acute myeloid leukemia;
Cancer
It is a CD33 x CD3 tandem diabody in early clinical development at Amphivena Therapeutics for the treatment of relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndromes and advanced solid tumors.

For more information about our anti-CD33 recombinant antibody products, please feel free to contact us at any time. Our dedicated team is here to assist you with any inquiries you may have, and we look forward to establishing a mutually beneficial partnership that supports your research goals.

  • 0
  • 0
Cart
    Go to compare

    Go to compare